{
  "id": "mhgap#risk_safety_bae28262",
  "content": "placebo-controlled randomised controlled trials. 200. DelBello MP, Kadakia A, Heller V, Singh R, Hagi K,\nLancet Psychiatry. 2018;5(8):653–63 (https://doi. Nosaka T et al. Systematic review and network\norg/10.1016/S2215-0366(18)30177-9). meta-analysis: efficacy and safety of second-\ngeneration antipsychotics in youths with bipolar\n194. Kishi T, Ikuta T, Matsui Y, Inada K, Matsuda Y,\ndepression. J Am Acad Child Adolesc Psychiatry.\nMishima K et al. Effect of discontinuation v.\n2022;61(2):243–54 (https://doi.org/10.1016/j.\nmaintenance of antipsychotic medication on\njaac.2021.03.021).\nrelapse rates in patients with remitted/stable\nfirst-episode psychosis: a meta-analysis. Psychol\nMed. 2019;49(5):772–9 (https://doi.org/10.1017/\nS0033291718001393).\n127\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\n201. Ciray RO, Hancer P, Tuncturk M, Emiroglu 209. mhGAP operations manual. Geneva: World\nNI. [Placebo-controlled pharmacological Health Organization; 2018 (https://iris.who.int/\ntrials in child and adolescents with bipolar handle/10665/275386).\ndisorder manic episode (BPD-ME): systematic\n210. Bighelli I, Rodolico A, García-Mieres H, Pitschel-\nreview, meta-analysis and a meta-regression\nWalz G, Hansen WP, Schneider-Thoma J et al.\non placebo response] (in Turkish). Turkish J\nPsychosocial and psychological interventions\nClinical Psychiatry. 2020;23:375–85 (https://doi.\nfor relapse prevention in schizophrenia: a\norg/10.5505/kpd.2020.45822).\nsystematic review and network meta-analysis.\n202. Kishi T, Ikuta T, Matsuda Y, Sakuma K, Okuya M, Lancet Psychiatry. 2021;8(11):969–80 (https://doi.",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "work",
      "risk_safety",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety placebo-controlled randomised controlled trials. 200. DelBello MP, Kadakia A, Heller V, Singh R, Hagi K,\nLancet Psychiatry. 2018;5(8):653–63 (https://doi. Nosaka T et al. Systematic review and network\norg/10.1016/S2215-0366(18)30177-9). meta-analysis: efficacy and safety of second-\ngeneration antipsychotics in youths with bipolar\n194. Kishi T, Ikuta T, Matsui Y, Inada K, Matsuda Y,\ndepression. J Am Acad Child Adolesc Psychiatry.\nMishima K et al. Effect of discontinuation v.\n2022;61(2):243–54 (https://doi.org/10.1016/j.\nmaintenance of antipsychotic medication on\njaac.2021.03.021).\nrelapse rates in patients with remitted/stable\nfirst-episode psychosis: a meta-analysis. Psychol\nMed. 2019;49(5):772–9 (https://doi.org/10.1017/\nS0033291718001393).\n127\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\n201. Ciray RO, Hancer P, Tuncturk M, Emiroglu 209. mhGAP operations manual. Geneva: World\nNI. [Placebo-controlled pharmacological Health Organization; 2018 (https://iris.who.int/\ntrials in child and adolescents with bipolar handle/10665/275386).\ndisorder manic episode (BPD-ME): systematic\n210. Bighelli I, Rodolico A, García-Mieres H, Pitschel-\nreview, meta-analysis and a meta-regression\nWalz G, Hansen WP, Schneider-Thoma J et al.\non placebo response] (in Turkish). Turkish J\nPsychosocial and psychological interventions\nClinical Psychiatry. 2020;23:375–85 (https://doi.\nfor relapse prevention in schizophrenia: a\norg/10.5505/kpd.2020.45822).\nsystematic review and network meta-analysis.\n202. Kishi T, Ikuta T, Matsuda Y, Sakuma K, Okuya M, Lancet Psychiatry. 2021;8(11):969–80 (https://doi. Placebo-controlled randomised controlled trials. 200."
}